Shares of Ind-Swift Laboratories gained as much as 10 per cent on Tuesday on the announcement that it is all set to commercially launch its key API - Fexofenadine, an AntiHistamine drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.
The company has tied up with a reputed generic player in the USA, which had filed the ANDA using the IndSwift Laboratories Limited DMF. The company has received commercial orders, and the supplies are beginning from the current quarter.